Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$80m Windfall Will Push 7 ADC Drug Candidates Into Clinic Within Two Years

This article was originally published in Scrip

Executive Summary

By generating $80m through its latest equity placement, oncology drug development company ADC Therapeutics (ADCT) says it is now well-funded to advance its portfolio of linked tumor-targeted antibody drug conjugates (ADCs) and plans to have seven drug candidates in human clinical trials by-mid 2017, two of which are partnered with AstraZeneca PLC's biologic's division MedImmune LLC.

You may also be interested in...



ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.

ADC Therapeutics Raises $105m To Reach Pivotal Studies

A second round of funding in just over a year is expected to allow the Lausanne, Switzerland-based company to reach the start of pivotal studies for its novel antibody-drug conjugates.

Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK

The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel